| Autor: |
Kotaskova, Jana, Tichy, Boris, Trbusek, Martin, Francova, Hana Skuhrova, Kabathova, Jitka, Malcikova, Jitka, Doubek, Michael, Brychtova, Yvona, Mayer, Jiri, Pospisilova, Sarka |
| Zdroj: |
The Journal of Molecular Diagnostics; May 2010, Vol. 12 Issue: 3 p328-334, 7p |
| Abstrakt: |
Chronic lymphocytic leukemia (CLL) is characterized by a monoclonal expansion of mature B-lymphocytes. Mutational status of the immunoglobulin variable heavy chain region(IGHV) gene stratifies CLL patients into two prognostic groups. We performed microarray analysis of CLL cells using the Agilent platform to detect the most important gene expression differences regarding IGHVstatus in CLL cells. We analyzed a cohort of 118 CLL patients with different IGHVmutational status and completely characterized all described prognostic markers using expression microarrays and quantitative real-time RT-PCR (reverse transcription PCR). We detected lymphocyte-activation gene 3(LAG3) as a novel prognostic marker: LAG3high expression in CLL cells correlates with unmutated IGHV(P< 0.0001) and reduced treatment-free survival (P= 0.0087). Furthermore, quantitative real-time RT-PCR analysis identified a gene-set (LAG3, LPL, ZAP70) whose overexpression is assigned to unmutated IGHVwith 90% specificity (P< 0.0001). Moreover, high expression of tested gene-set and unmutated IGHVequally correlated with reduced treatment-free survival (P= 7.7 * 10−11vs. P= 1.8 * 10−11). Our results suggest that IGHV status can be precisely assessed using the expression analysis of LAG3, LPL, and ZAP70genes. Expression data of tested markers provides a similar statistical concordance with treatment-free survival as that of the IGHV status itself. Our findings contribute to the elucidation of CLL pathogenesis and provide novel prognostic markers for possible application in routine diagnostics. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
